| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter Infections | 21 | 2013 | 55 | 3.940 |
Why?
|
| Stomach Neoplasms | 18 | 2018 | 73 | 3.590 |
Why?
|
| Helicobacter felis | 12 | 2013 | 17 | 1.960 |
Why?
|
| Bone Marrow Cells | 9 | 2010 | 231 | 1.840 |
Why?
|
| Gastric Mucosa | 14 | 2014 | 48 | 1.650 |
Why?
|
| Helicobacter pylori | 11 | 2010 | 58 | 1.530 |
Why?
|
| Adenocarcinoma | 7 | 2018 | 323 | 1.170 |
Why?
|
| fas Receptor | 4 | 2009 | 54 | 1.100 |
Why?
|
| Gastritis | 6 | 2014 | 17 | 1.000 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2014 | 192 | 0.920 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 299 | 0.920 |
Why?
|
| Stromal Cells | 4 | 2014 | 65 | 0.900 |
Why?
|
| Epithelial Cells | 5 | 2014 | 374 | 0.740 |
Why?
|
| Helicobacter | 2 | 2012 | 3 | 0.720 |
Why?
|
| Animals | 39 | 2023 | 19646 | 0.680 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 215 | 0.680 |
Why?
|
| Cell Proliferation | 8 | 2021 | 942 | 0.650 |
Why?
|
| Mice | 27 | 2023 | 10273 | 0.650 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 351 | 0.610 |
Why?
|
| Precancerous Conditions | 4 | 2018 | 72 | 0.600 |
Why?
|
| Inflammation | 8 | 2023 | 1096 | 0.580 |
Why?
|
| Neoplastic Stem Cells | 3 | 2007 | 201 | 0.540 |
Why?
|
| Mice, Inbred C57BL | 14 | 2021 | 3193 | 0.530 |
Why?
|
| Disease Models, Animal | 8 | 2014 | 2068 | 0.470 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 76 | 0.450 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 32 | 0.440 |
Why?
|
| Stem Cells | 2 | 2006 | 257 | 0.430 |
Why?
|
| Signal Transduction | 10 | 2014 | 2886 | 0.420 |
Why?
|
| Apoptosis | 6 | 2009 | 1038 | 0.410 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 255 | 0.410 |
Why?
|
| Neoplasms | 3 | 2007 | 1244 | 0.400 |
Why?
|
| Colitis | 2 | 2023 | 76 | 0.380 |
Why?
|
| Fas Ligand Protein | 2 | 2009 | 39 | 0.370 |
Why?
|
| Myofibroblasts | 1 | 2010 | 12 | 0.360 |
Why?
|
| Endothelium | 1 | 2010 | 18 | 0.360 |
Why?
|
| Barrett Esophagus | 1 | 2010 | 33 | 0.350 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 30 | 0.350 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 75 | 0.350 |
Why?
|
| Liver Neoplasms | 2 | 2009 | 277 | 0.330 |
Why?
|
| Mucins | 3 | 2006 | 23 | 0.330 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 40 | 0.330 |
Why?
|
| Gastrins | 6 | 2014 | 6 | 0.320 |
Why?
|
| Cytokines | 6 | 2020 | 905 | 0.320 |
Why?
|
| Tea | 1 | 2009 | 26 | 0.320 |
Why?
|
| Muscle Proteins | 3 | 2006 | 109 | 0.310 |
Why?
|
| Mutation | 2 | 2021 | 2443 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 3 | 2009 | 724 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 40 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 44 | 0.290 |
Why?
|
| Genes, p53 | 1 | 2007 | 53 | 0.290 |
Why?
|
| Hedgehog Proteins | 3 | 2014 | 113 | 0.290 |
Why?
|
| Plant Extracts | 1 | 2009 | 161 | 0.280 |
Why?
|
| Humans | 29 | 2021 | 59454 | 0.280 |
Why?
|
| Point Mutation | 1 | 2007 | 163 | 0.280 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 167 | 0.280 |
Why?
|
| Immunity, Innate | 3 | 2021 | 762 | 0.270 |
Why?
|
| Male | 17 | 2021 | 27556 | 0.270 |
Why?
|
| Stomach | 4 | 2018 | 84 | 0.270 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 13 | 0.260 |
Why?
|
| Receptor Aggregation | 1 | 2005 | 5 | 0.260 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 645 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 483 | 0.240 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2005 | 179 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2004 | 18 | 0.230 |
Why?
|
| Toxoplasma | 1 | 2004 | 30 | 0.230 |
Why?
|
| Actins | 1 | 2005 | 260 | 0.220 |
Why?
|
| Lymphocytes | 2 | 2020 | 193 | 0.220 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2099 | 0.210 |
Why?
|
| Mice, Knockout | 6 | 2010 | 1988 | 0.210 |
Why?
|
| Mice, SCID | 3 | 2014 | 506 | 0.210 |
Why?
|
| Cell Differentiation | 4 | 2013 | 1294 | 0.210 |
Why?
|
| Mice, Inbred NOD | 3 | 2014 | 511 | 0.200 |
Why?
|
| Metaplasia | 3 | 2010 | 18 | 0.200 |
Why?
|
| Cell Line, Tumor | 4 | 2011 | 1373 | 0.200 |
Why?
|
| Blood Bactericidal Activity | 1 | 2002 | 70 | 0.190 |
Why?
|
| Neuropeptides | 1 | 2002 | 82 | 0.190 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 152 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2002 | 86 | 0.180 |
Why?
|
| Ubiquitination | 1 | 2021 | 106 | 0.180 |
Why?
|
| Myeloid Cells | 1 | 2021 | 92 | 0.180 |
Why?
|
| Dysbiosis | 1 | 2021 | 56 | 0.180 |
Why?
|
| Fibroblasts | 2 | 2014 | 370 | 0.180 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2020 | 8 | 0.170 |
Why?
|
| Peptides | 4 | 2018 | 545 | 0.170 |
Why?
|
| Interferon-gamma | 4 | 2018 | 542 | 0.160 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 2 | 2009 | 9 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 214 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 66 | 0.150 |
Why?
|
| Epithelium | 2 | 2010 | 97 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 847 | 0.150 |
Why?
|
| Atrophy | 3 | 2006 | 63 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 582 | 0.140 |
Why?
|
| Fluorouracil | 2 | 2014 | 54 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2018 | 116 | 0.140 |
Why?
|
| Transfection | 2 | 2009 | 674 | 0.130 |
Why?
|
| Disease Progression | 3 | 2007 | 1046 | 0.130 |
Why?
|
| Receptors, Histamine H2 | 2 | 2006 | 2 | 0.130 |
Why?
|
| Mice, Transgenic | 4 | 2009 | 1223 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2007 | 133 | 0.130 |
Why?
|
| Coculture Techniques | 2 | 2009 | 93 | 0.130 |
Why?
|
| Trefoil Factor-2 | 3 | 2006 | 6 | 0.130 |
Why?
|
| Female | 7 | 2021 | 30893 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2021 | 841 | 0.120 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2014 | 43 | 0.120 |
Why?
|
| HIV-1 | 1 | 2020 | 705 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 38 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2009 | 673 | 0.110 |
Why?
|
| Rats | 2 | 2007 | 1913 | 0.100 |
Why?
|
| Middle Aged | 5 | 2014 | 16256 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 74 | 0.090 |
Why?
|
| Time Factors | 3 | 2007 | 3578 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 404 | 0.090 |
Why?
|
| Models, Biological | 2 | 2007 | 1141 | 0.090 |
Why?
|
| Genes, APC | 1 | 2010 | 9 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2010 | 50 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 183 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 159 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 233 | 0.090 |
Why?
|
| Ethanol | 1 | 2013 | 307 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 45 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 155 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 37 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 223 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 304 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2010 | 79 | 0.080 |
Why?
|
| Receptor, Cholecystokinin B | 2 | 2006 | 2 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 43 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 178 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2010 | 174 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 35 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 59 | 0.080 |
Why?
|
| Homeostasis | 2 | 2023 | 342 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 343 | 0.080 |
Why?
|
| Aged | 4 | 2014 | 13340 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2009 | 182 | 0.080 |
Why?
|
| Hepatitis | 1 | 2009 | 55 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 454 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 196 | 0.080 |
Why?
|
| Cell Movement | 1 | 2010 | 422 | 0.080 |
Why?
|
| Gastritis, Atrophic | 2 | 2010 | 3 | 0.080 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2007 | 4 | 0.070 |
Why?
|
| Fibrosarcoma | 1 | 2007 | 13 | 0.070 |
Why?
|
| Hepatocytes | 1 | 2009 | 191 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 97 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 264 | 0.070 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2007 | 74 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2009 | 105 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 77 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 328 | 0.070 |
Why?
|
| Adult | 4 | 2010 | 15767 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2007 | 176 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 74 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 501 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 255 | 0.060 |
Why?
|
| Cytochalasin D | 1 | 2005 | 19 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 143 | 0.060 |
Why?
|
| Benzodiazepinones | 1 | 2005 | 2 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2007 | 461 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 11 | 0.060 |
Why?
|
| Intestinal Mucosa | 2 | 2023 | 219 | 0.060 |
Why?
|
| Tetracycline | 1 | 2005 | 20 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 245 | 0.060 |
Why?
|
| Adipocytes | 1 | 2007 | 252 | 0.060 |
Why?
|
| Phenylurea Compounds | 1 | 2005 | 29 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2007 | 858 | 0.060 |
Why?
|
| Triazoles | 1 | 2005 | 53 | 0.060 |
Why?
|
| Parietal Cells, Gastric | 1 | 2004 | 1 | 0.060 |
Why?
|
| Helicobacter hepaticus | 1 | 2004 | 2 | 0.060 |
Why?
|
| Keratins | 1 | 2004 | 31 | 0.060 |
Why?
|
| Cell Fusion | 1 | 2004 | 45 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 856 | 0.060 |
Why?
|
| Intestines | 2 | 2021 | 156 | 0.060 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 32 | 0.060 |
Why?
|
| Virulence | 1 | 2004 | 189 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 1131 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2006 | 258 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2004 | 195 | 0.060 |
Why?
|
| Glycine | 1 | 2004 | 45 | 0.060 |
Why?
|
| Cadherins | 1 | 2003 | 67 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 157 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 5098 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 452 | 0.050 |
Why?
|
| Trefoil Factor-3 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Gastric Acid | 1 | 2002 | 10 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 442 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 35 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 150 | 0.050 |
Why?
|
| Urease | 1 | 2002 | 9 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 439 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2002 | 57 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2002 | 56 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2002 | 57 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 233 | 0.050 |
Why?
|
| Culture Media | 1 | 2002 | 77 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1129 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 667 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 453 | 0.050 |
Why?
|
| Phenotype | 1 | 2004 | 1150 | 0.050 |
Why?
|
| Macrophages | 1 | 2006 | 1004 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 237 | 0.040 |
Why?
|
| Biopsy | 1 | 2002 | 375 | 0.040 |
Why?
|
| Mitochondria | 1 | 2023 | 336 | 0.040 |
Why?
|
| Acute Disease | 1 | 2002 | 658 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 71 | 0.040 |
Why?
|
| Neutrophils | 1 | 2002 | 352 | 0.040 |
Why?
|
| Monocytes | 1 | 2021 | 345 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 472 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1094 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1055 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 555 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2018 | 54 | 0.040 |
Why?
|
| Interleukins | 1 | 2018 | 78 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 276 | 0.040 |
Why?
|
| Diet | 1 | 2002 | 634 | 0.040 |
Why?
|
| Antibodies | 1 | 2018 | 176 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2018 | 173 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 155 | 0.030 |
Why?
|
| Microbiota | 1 | 2018 | 103 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2018 | 221 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 879 | 0.030 |
Why?
|
| RNA Interference | 1 | 2018 | 590 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Focal Adhesions | 1 | 2013 | 23 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 5010 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 193 | 0.030 |
Why?
|
| HIV Infections | 1 | 2020 | 920 | 0.030 |
Why?
|
| Succinimides | 1 | 2011 | 17 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2011 | 29 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 18 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 180 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 376 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 195 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 79 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 60 | 0.020 |
Why?
|
| Rituximab | 1 | 2009 | 82 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 169 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 363 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 233 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 427 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 354 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 254 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 483 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 498 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 790 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2006 | 64 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 98 | 0.020 |
Why?
|
| Achlorhydria | 1 | 2005 | 1 | 0.020 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2005 | 2 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 448 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 291 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 525 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2004 | 73 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2004 | 220 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 807 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 702 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 348 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 434 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 553 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 139 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 645 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2013 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 4320 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 1572 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 5174 | 0.010 |
Why?
|